ECSP13012858A - Derivados de piperidina puenteada - Google Patents
Derivados de piperidina puenteadaInfo
- Publication number
- ECSP13012858A ECSP13012858A ECSP13012858A ECSP13012858A EC SP13012858 A ECSP13012858 A EC SP13012858A EC SP13012858 A ECSP13012858 A EC SP13012858A EC SP13012858 A ECSP13012858 A EC SP13012858A
- Authority
- EC
- Ecuador
- Prior art keywords
- lower alkyl
- halogen
- ring
- alkyl substituted
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula:en la que:hetarilo I es un grupo heteroarilo de cinco o seis eslabones, que contiene de 1 a 3 heteroátomos elegidos entre S y N; hetarilo II es un grupo heteroarilo de seis eslabones, que contiene de 1 a 3 heteroátomos elegidos entre S y N, o es un sistema cíclico de dos miembros que contiene de 1 a 4 heteroátomos elegidos entre S y N, de los que por lo menos un anillo es de naturaleza aromática; R1 es alquilo inferior, alcoxi inferior, alquilo inferior sustituido por halógeno o halógeno; R2 es alquilo inferior, alquilo inferior sustituido por halógeno, halógeno, alcoxi inferior, cicloalquilo sustituido por alquilo inferior o alquilo inferior sustituido por halógeno, o es alquilo inferior sustituido por hidroxi, o es furilo, o es O-bencilo, -(CH2)p-fenilo, opcionalmente sustituido por halógeno, alcoxi inferior, alquilo inferior sustituido por halógeno, alquilo inferior o por ciano;R3 es hidrógeno o alquilo inferior;Y es -(CH2)n-, -CH2OCH2-, -CH2O-, CH2S-, -CH2SCH2- y está unido a dos de los átomos de carbono del anillo, la unión se realiza con los átomos de carbono "a" y "b" del anillo o con los átomos de carbono "c" y "d" del anillo;p es el número 0 ó 1;m es el número 0, 1 ó 2; si m es 2, entonces R1 puede ser igual o diferente; n es el número 2 ó 3;"o" es el número 0, 1 ó 2, si "o" es 2, entonces R2 puede ser igual o diferente;o a sus sales de adición de ácido farmacéuticamente activas.Los compuestos presentes de la fórmula I son moduladores de beta-amiloide y por ello pueden ser útiles para el tratamiento o prevención de una enfermedad asociada con la deposición de ß-amiloide en el cerebro, en particular la enfermedad de Alzheimer y otras enfermedades, como son la angiopatía cerebral amiloide, la hemorragia cerebral hereditaria con amiloidosis de tipo Dutch (HCHWA-D), la demencia multiinfarto, la demencia pugilística y el síndrome de Down.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11156587 | 2011-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP13012858A true ECSP13012858A (es) | 2013-10-31 |
Family
ID=45757448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP13012858 ECSP13012858A (es) | 2011-03-02 | 2013-08-30 | Derivados de piperidina puenteada |
Country Status (21)
Country | Link |
---|---|
US (1) | US8703763B2 (es) |
EP (1) | EP2681214B1 (es) |
JP (1) | JP5753591B2 (es) |
KR (1) | KR101550122B1 (es) |
CN (1) | CN103403003B (es) |
BR (1) | BR112013021924A2 (es) |
CA (1) | CA2824239A1 (es) |
CL (1) | CL2013002474A1 (es) |
CO (1) | CO6761320A2 (es) |
CR (1) | CR20130358A (es) |
EA (1) | EA025035B1 (es) |
EC (1) | ECSP13012858A (es) |
IL (1) | IL227251A (es) |
MA (1) | MA34964B1 (es) |
MX (1) | MX2013009031A (es) |
MY (1) | MY167264A (es) |
PE (1) | PE20140250A1 (es) |
SG (1) | SG193239A1 (es) |
UA (1) | UA110368C2 (es) |
WO (1) | WO2012116965A1 (es) |
ZA (1) | ZA201305322B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8703863B2 (en) * | 2007-04-25 | 2014-04-22 | Nissan Chemical Industries, Ltd. | Polyimide precursor, polyimide, and coating solution for under layer film for image formation |
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
WO2017042114A1 (en) * | 2015-09-09 | 2017-03-16 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
EP4360707A2 (en) | 2015-11-12 | 2024-05-01 | F. Hoffmann-La Roche AG | Compositions for treating spinal muscular atrophy |
EP3848035A1 (en) | 2015-12-10 | 2021-07-14 | PTC Therapeutics, Inc. | 1,4-disubstituted pyridazine compounds for treating huntington's disease |
WO2017097728A1 (en) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
WO2018001918A1 (en) | 2016-06-27 | 2018-01-04 | F. Hoffmann-La Roche Ag | Triazolopyridines as gamma-secretase modulators |
CN109311877B (zh) * | 2016-07-14 | 2021-05-28 | 豪夫迈·罗氏有限公司 | 稠合嘧啶衍生物 |
WO2018039477A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating functional decline |
AR109829A1 (es) * | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
CN109476670B (zh) * | 2016-10-04 | 2022-06-28 | 豪夫迈·罗氏有限公司 | 二环杂芳基衍生物 |
AR110001A1 (es) * | 2016-11-01 | 2019-02-13 | Hoffmann La Roche | Derivados heteroarilo bicíclicos |
WO2018087018A1 (en) | 2016-11-08 | 2018-05-17 | F. Hoffmann-La Roche Ag | Phenoxytriazoles |
RU2757276C2 (ru) | 2016-12-16 | 2021-10-12 | Пайплайн Терапьютикс, Инк. | Способы лечения кохлеарной синаптопатии |
SG11201911615WA (en) | 2017-06-05 | 2020-01-30 | Ptc Therapeutics Inc | Compounds for treating huntington's disease |
CA3067592A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
WO2019121596A1 (en) * | 2017-12-19 | 2019-06-27 | Boehringer Ingelheim International Gmbh | Triazolo pyridines as modulators of gamma-secretase |
JP7335248B2 (ja) * | 2018-01-22 | 2023-08-29 | エフ. ホフマン-ラ ロシュ アーゲー | トリアゾロ-アゼピン誘導体 |
WO2019191092A1 (en) | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
JP7421507B2 (ja) | 2018-06-27 | 2024-01-24 | ピーティーシー セラピューティクス, インコーポレイテッド | ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物 |
WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
HUE064554T2 (hu) * | 2018-09-03 | 2024-03-28 | Hoffmann La Roche | Bicikluszos heteroaril származékok |
BR112021009443A2 (pt) * | 2018-12-13 | 2021-08-17 | F. Hoffmann-La Roche Ag | derivados de 7-fenóxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-di-hidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina e compostos relacionados como moduladores de gama-secretase para o tratamento da doença de alzheimer. |
CN113372364B (zh) * | 2020-03-10 | 2024-05-31 | 明慧医药(上海)有限公司 | 一类jak激酶抑制剂及其制备和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432985B2 (en) * | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
BRPI0616839A2 (pt) * | 2005-10-06 | 2013-01-01 | Nippon Soda Co | agentes para controle de praga, e, compostos de amina cìclicos |
JP5328816B2 (ja) | 2008-02-22 | 2013-10-30 | エフ.ホフマン−ラ ロシュ アーゲー | アミロイドβの調節薬 |
US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
-
2012
- 2012-02-27 US US13/405,404 patent/US8703763B2/en not_active Expired - Fee Related
- 2012-02-28 BR BR112013021924-6A patent/BR112013021924A2/pt not_active IP Right Cessation
- 2012-02-28 WO PCT/EP2012/053301 patent/WO2012116965A1/en active Application Filing
- 2012-02-28 MA MA36238A patent/MA34964B1/fr unknown
- 2012-02-28 MX MX2013009031A patent/MX2013009031A/es active IP Right Grant
- 2012-02-28 UA UAA201311595A patent/UA110368C2/uk unknown
- 2012-02-28 SG SG2013065107A patent/SG193239A1/en unknown
- 2012-02-28 EP EP12705884.0A patent/EP2681214B1/en not_active Not-in-force
- 2012-02-28 CN CN201280011284.3A patent/CN103403003B/zh not_active Expired - Fee Related
- 2012-02-28 JP JP2013555846A patent/JP5753591B2/ja not_active Expired - Fee Related
- 2012-02-28 KR KR1020137025946A patent/KR101550122B1/ko not_active IP Right Cessation
- 2012-02-28 CA CA2824239A patent/CA2824239A1/en not_active Abandoned
- 2012-02-28 MY MYPI2013003198A patent/MY167264A/en unknown
- 2012-02-28 PE PE2013002000A patent/PE20140250A1/es not_active Application Discontinuation
- 2012-02-28 EA EA201391209A patent/EA025035B1/ru not_active IP Right Cessation
-
2013
- 2013-06-27 IL IL227251A patent/IL227251A/en active IP Right Grant
- 2013-07-15 ZA ZA2013/05322A patent/ZA201305322B/en unknown
- 2013-07-23 CR CR20130358A patent/CR20130358A/es unknown
- 2013-07-25 CO CO13176486A patent/CO6761320A2/es unknown
- 2013-08-28 CL CL2013002474A patent/CL2013002474A1/es unknown
- 2013-08-30 EC ECSP13012858 patent/ECSP13012858A/es unknown
Also Published As
Publication number | Publication date |
---|---|
NZ612525A (en) | 2015-08-28 |
CR20130358A (es) | 2013-10-03 |
EP2681214B1 (en) | 2017-03-22 |
JP2014506903A (ja) | 2014-03-20 |
CA2824239A1 (en) | 2012-09-07 |
MA34964B1 (fr) | 2014-03-01 |
CO6761320A2 (es) | 2013-09-30 |
CN103403003A (zh) | 2013-11-20 |
EA025035B1 (ru) | 2016-11-30 |
UA110368C2 (en) | 2015-12-25 |
AU2012222426A1 (en) | 2013-07-11 |
EA201391209A1 (ru) | 2013-12-30 |
WO2012116965A1 (en) | 2012-09-07 |
ZA201305322B (en) | 2014-04-30 |
KR20130140142A (ko) | 2013-12-23 |
KR101550122B1 (ko) | 2015-09-03 |
CL2013002474A1 (es) | 2014-05-30 |
US8703763B2 (en) | 2014-04-22 |
PE20140250A1 (es) | 2014-03-12 |
SG193239A1 (en) | 2013-10-30 |
US20120225884A1 (en) | 2012-09-06 |
MX2013009031A (es) | 2013-09-02 |
EP2681214A1 (en) | 2014-01-08 |
MY167264A (en) | 2018-08-14 |
CN103403003B (zh) | 2016-09-14 |
JP5753591B2 (ja) | 2015-07-22 |
IL227251A (en) | 2016-09-29 |
IL227251A0 (en) | 2013-09-30 |
BR112013021924A2 (pt) | 2020-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP13012858A (es) | Derivados de piperidina puenteada | |
AR080177A1 (es) | Derivados de piperidina, un procedimiento para su preparacion, y su uso en medicamentos para el tratamiento de enfermedades mentales asociadas a la deposicion del beta-amiloide en el cerebro. | |
AR074304A1 (es) | Moduladores heterociclicos de gamma- secretasa | |
AR121661A2 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
CL2018000036A1 (es) | Derivados etinilo | |
AR070130A1 (es) | Compuestos moduladores de beta-amiloide, un proceso para su obtencion, el uso del compuesto para la fabricacion de un medicamento y dicho medicamento | |
PE20200008A1 (es) | Isoquinolinas como inhibidores de hpk1 | |
AR107010A1 (es) | Derivados de piperidina puenteados | |
AR096371A1 (es) | 2-fenilimidazo[1,2-a]pirimidinas | |
AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
AR105965A1 (es) | Derivados de piperidina puenteados | |
AR088352A1 (es) | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina | |
AR080083A1 (es) | Moduladores de gamma-secretasa | |
AR092628A1 (es) | Piridinonas biciclicas | |
AR070437A1 (es) | Moduladores de beta - amiloide | |
AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
AR110001A1 (es) | Derivados heteroarilo bicíclicos | |
AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
AR110122A1 (es) | Fenoxitriazoles | |
AR083798A1 (es) | Inhibidores selectivos de glucosidasas y sus usos | |
AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
AR109829A1 (es) | Derivados de piperidina puenteados | |
AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
AR078321A1 (es) | Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9) |